1-8 of 8
Larry Rubinstein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B138: Pharmacodynamics-driven phase 2 trial of talazoparib in patients with advanced solid tumors and aberrations in genes involved in DNA damage response

Free
Brian Ko, Geraldine H O'Sullivan Coyne, Abdul Rafeh Naqash, Thomas J George, David DeRemer, Larry Rubinstein, Jennifer Zlott, Deborah Wilsker, Donna Ketchum, Stephanie Runkle, Katherine V Ferry-Galow, Ralph E Parchment, Naoko Takebe, Sarah Shin, Andrea R Voth, Jiuping Ji, S. Percy Ivy, James H Doroshow, Alice P Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B138.
https://doi.org/10.1158/1535-7163.TARG-23-B138
Published: 01 December 2023
View article titled, Abstract B138: Pharmacodynamics-driven phase 2 trial of talazoparib in patients with advanced solid tumors and aberrations in genes involved in DNA damage response
Journal Articles

Abstract P049: Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with advanced non-small cell lung cancer

Free
Mohamad A. Salkeni, Geraldine O’Sullivan Coyne, Jennifer Zlott, Naoko Takebe, Ning Ma, Larry Rubinstein, Richard Piekarz, Jared Foster, Brandon Miller, Ralph Parchment, Abdul R. Naqash, Andrea Voth, James Doroshow, Alice Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P049.
https://doi.org/10.1158/1535-7163.TARG-21-P049
Published: 01 December 2021
View article titled, Abstract P049: Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with advanced non-small cell lung cancer
Journal Articles

Abstract B018: Restoration of p16INK4A expression in circulating tumor cells in patients with advanced solid tumors treated with deoxycytidine analogs and associated dynamic EMT phenotypic changes

Free
Lihua Wang, Brandon Miller, Sonny Khin, Geraldine O’Sullivan-Coyne, Alice P. Chen, Shivaani Kummar, Naoko Takebe, Kate Ferry-Galow, Ralph E. Parchment, Larry Rubinstein, Richard Piekarz, Edward M. Newman, James H. Doroshow, Robert J. Kinders
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B018.
https://doi.org/10.1158/1535-7163.TARG-19-B018
Published: 01 December 2019
View article titled, Abstract B018: Restoration of p16INK4A expression in circulating tumor cells in patients with advanced solid tumors treated with deoxycytidine analogs and associated dynamic EMT phenotypic changes
Journal Articles

Abstract A071: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes

Free
Sabrina S. Khan, Geraldine O'Sullivan, Larry Rubinstein, Shivaani Kummar, Lamin Juwara, Jennifer Zlott, Arjun Mittra, Murielle Hogu, Jerry Collins, Apurva Srivastava, Brandon Miller, Ralph E. Parchment, Christopher S. Hourigan, Steven Pavletic, James Doroshow, Alice P. Chen, Naoko Takebe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A071.
https://doi.org/10.1158/1535-7163.TARG-19-A071
Published: 01 December 2019
View article titled, Abstract A071: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes
Journal Articles

Abstract B12: DNA methyltransferase 3A expression in cancer cells following treatment with DNMT inhibitors and in human solid tumors

Free
Sherry X. Yang, Dat Nguyen, Larry Rubinstein, Alice P. Chen, James H. Doroshow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B12.
https://doi.org/10.1158/1535-7163.TARG-15-B12
Published: 01 December 2015
View article titled, Abstract B12: DNA methyltransferase 3A expression in cancer cells following treatment with DNMT inhibitors and in human solid tumors
Journal Articles

Abstract A46: A novel immunoassay (ELISA) for quantitative gamma-H2AX detection and pharmacodynamic monitoring of DNA damage induced by chemotherapeutic agents and PARP inhibitors.

Free
Jay Ji, Yiping Zhang, Robert Kinders, Christophe Redon, Stephanie Solier, Keli Agama, Yves Pommier, William Bonner, Melinda Hollingshead, Larry Rubinstein, Alice Chen, Shivaani Kummar, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A46.
https://doi.org/10.1158/1535-7163.TARG-11-A46
Published: 12 November 2011
View article titled, Abstract A46: A novel immunoassay (ELISA) for quantitative gamma-H2AX detection and pharmacodynamic monitoring of DNA damage induced by chemotherapeutic agents and PARP inhibitors.
Journal Articles

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

Free
Peter J. Houghton, Christopher L. Morton, Richard Gorlick, Richard B. Lock, Hernan Carol, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, E. Anders Kolb, Jianrong Wu, Amy W. Wozniak, Catherine A. Billups, Larry Rubinstein, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 101–112.
https://doi.org/10.1158/1535-7163.MCT-09-0952
Published: 12 January 2010
View article titled, Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
Open the PDF for Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program in another window
Includes: Supplementary data
Journal Articles

Abstract A98: Safety, efficacy and efficiency of phase 1 single agent trials using the accelerated titration (ATD) versus modified Fibonacci designs (STD)

Free
Janet E. Dancey, Igor Espinoza‐Delgado, Andriana Papaconstantinou, Joan Saunders, Larry Rubinstein
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A98.
https://doi.org/10.1158/1535-7163.TARG-09-A98
Published: 10 December 2009
View article titled, Abstract A98: Safety, efficacy and efficiency of phase 1 single agent trials using the accelerated titration (ATD) versus modified Fibonacci designs (STD)